Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis

Lupus Nephritis Clinical Trial

Official title:

Comparison Between Tacrolimus and Mycophenolate Mofetil for Induction of Remission in Lupus Nephritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01580865
• Other study ID #: PRG-LN-11-01
• Status: Completed
• Phase: N/A
• Start date: May 2012
• Est. completion date: March 2017

Study information

• Verified date: September 2018
• Source: Ramathibodi Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, multi-center, randomized, controlled, trial to compare tacrolimus with mycophenolate mofetil (MMF) for induces complete remission in lupus nephritis patients. The study duration is one year.

Research hypothesis

• The proportion of patients who have achieved complete remission between regimen of tacrolimus plus prednisolone is greater than MMF plus prednisolone as an induction therapy in lupus nephritis.

Description:

The patients with a pathological diagnosis of active lupus nephritis whom are currently followed up or referred to outpatient department (OPD) of 7 participating medical centers in Thailand. Patients who come to attend will be selected according to the inclusion and exclusion criteria.

Outcome measurements

• The patients will be follow-up for 1 year and will be evaluated for clinical manifestations and laboratory investigations of lupus nephritis and any adverse effects of therapy on each visit.

• Blood pressure and laboratory assessments, including complete blood cell count, urinalysis, urine protein creatinine ratio (UPCR), and kidney and liver function, will be performed at each visit for 24 weeks and at the end of study (48 weeks).

• Serum anti-double-stranded DNA antibodies and serum C3 will be measured every 8 weeks after treatment until 24 weeks and at the end of study (48 weeks).

• A fasting lipid profile will be also measured every 8 weeks until 24 weeks and at the end of study (48 weeks).

• Renal and extrarenal disease activity of SLE was measured using the SLEDAI2K. The SLEDAI2K will be evaluated at the time of entry into the study and every 8 weeks after treatment until 24 weeks and at the end of study (48 weeks).

• SLICC damage index, SF-36, EQ5D, and SLEQOL will be evaluated at the time of entry, at 24 weeks, and at the end of the study.

• Patients' serum and urine (blood 3ml and urine 50 ml) will be collected at baseline, 2nd week, 4th week, 12th week, and 48th week for further analysis of biomarkers in the future.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 84
• Est. completion date: March 2017
• Est. primary completion date: March 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• The patient who had biopsy-proven lupus nephritis class III, IV or V according to the International Society of Nephrology (ISN)/Renal Pathology Society (RPS) 2003 classification (ISN/RPS2003) within 16 weeks of randomization and had ANA or anti-dsDNA positive.

• Laboratory tests documented the presence of active nephritis, defined as proteinuria (protein excretion >1 g/24 h or spot UPCR > 1 for at least two samples) or increased serum creatinine level (>0.3 mg/dL of baseline but less than 2.0 mg/dl) with active urinary sediment (any of >5 red blood cells/high-power field, >5 white blood cells/high-power field, or red blood cell casts in the absence of infection or other causes).

• Willingness to participate in the study, and be able to read and provide informed consent.

Exclusion Criteria:

• Severe extra-renal manifestations that may require high-dose steroids or other immunomodulating treatments. The definition of severe extra-renal diseases in this investigation are defined by

• Active central nervous system deemed to be severe or progressive and/ or associated with significant cognitive impairment leading to inability to provide informed consent and/ or comply with the protocol.

• Any condition, including clinical findings or the laboratory results, which the investigators consider the patients have high disease activity and need high dose steroid and immunosuppressive drugs or other therapy depending on investigator opinion.

• Severe myocarditis with congestive heart failure or renal failure.

• Previous therapy with calcineurin inhibitor or MMF or CYC within the previous 4 months before randomization.

• Allergy with macrolide antibiotics.

• Uncontrolled hypertension (systolic blood pressure =160mmHg or diastolic blood pressure =100mmHg) at screening day.

• Severely deteriorated renal function or rapid progressive crescentic Glomerulonephritis.

• Severe myocarditis or cardiomyopathy which may or may not be related to SLE

• Patients who have thrombotic microangiopathy who require treatment with plasmapheresis or IVIG.

• Severe infection or active TB.

• Active hepatitis and evidence of chronic liver disease.

• HIV infection.

• Diabetes mellitus.

• Women who were pregnant or unwilling to use contraception.

• Patients who response to steroid (complete remission) during the run in period (4 weeks).

• Known hypersensitivity or contraindication to MMF, mycophenolic acid (MPA), tacrolimus, corticosteroids or any components of these drug products.

Related Conditions & MeSH terms

• Lupus Nephritis
• Nephritis

Intervention

Drug:
• Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis
Patients were randomly assigned to receive regimen I or II: TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group). TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter. MMF was initiated at a dose of 500 mg twice daily (for patients > 50 Kg and Estimated Glomerular Filtration rate (eGFR) > 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. Patients received concomitant prednisone at a dose of 0.5-0.7 mg/kg/d (maximum 60 mg/day), with tapering by 5-10 mg/day every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage was maintained until the end of 24 weeks.

Locations

Country	Name	City	State
Thailand	Ramathibodi Hospital	Rahathevi	Bangkok

Sponsors (7)

Lead Sponsor	Collaborator
Ramathibodi Hospital	King Chulalongkorn Memorial Hospital, Maharaj Nakorn Chiang Mai Hospital, Rajavithi Hospital, Siriraj Hospital, Songklanagarind Hospital, Srinagarind Hospital, Khon Kaen University

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete remission	Return of serum creatinine to previous baseline, plus a decline in the UPCR to <500 mg/g (<50 mg/mmol)	1 year
Secondary	Partial remission	Stabilization (±25%), or improvement of serum creatinine, but not to normal, plus a =50% decrease in UPCR. If there was nephrotic-range proteinuria (UPCR =3000 mg/g [=300 mg/mmol]), improvement requires a =50% reduction in UPCR, and a UPCR <3000 mg/g [<300 mg/mmol]	1 year
Secondary	Urine protein to creatinine ratio (UPCR)	g/day	1 year
Secondary	Serum creatinine	mg/dL	1 year
Secondary	Glomerular filtration rate (GFR)	mL/min/1.73m2	1 year
Secondary	Adverse events	Infection, leukopenia, gastrointestinal (GI) symptoms, new onset diabetes mellitus (DM)/hyperglycemia	1 year
Secondary	Serious dverse events	Hospitalization, death	1 year
Secondary	EQ5D	The Euro quality of life -5 Dimensions	1 year
Secondary	SF36	The 36-Item Short Form Health Survey	1 year
Secondary	SLEQOL	Systemic Lupus Erythematosus Quality of Life Questionnaire	1 year
Secondary	SLEDAI-2K	Systemic Lupus Erythematosus Disease Activity Index 2000	1 year